ICON Completes CAP Accreditation of Central Labs in Singapore and India
Dublin, Ireland, April 7th, 2009-ICON plc, NASDAQ: ICLR; ISIN:IE0005711209),
a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that its Central Laboratories in Singapore and Bangalore, India, have received accreditation from the College of American Pathologists (CAP). ICON’s Bangalore facility was rewarded for its high quality by passing the rigorous accreditation process within only four months of opening. ICON now has a global network of CAP accredited laboratories in Farmingdale, New York, Dublin, Ireland, Singapore and Bangalore, ensuring the highest standards of excellence in laboratory services.
“CAP is the gold standard by which all laboratories are measured and this is a great achievement,” commented Bob Scott-Edwards, President of ICON Central Laboratories. “The speed at which we received CAP accreditation, in particular for our Bangalore facility, is testament to our stringent quality standards, our state of the art laboratory facilities and the expertise of our global team. We are committed to maintaining excellence in laboratory services through the provision of extensive testing and sample management services in key regions for global clinical studies.”
The CAP Laboratory Accreditation Program is an internationally recognised program that helps laboratories achieve the highest standards of excellence to positively impact patient care. Based on rigorous accreditation standards, the goal of the program is to improve patient safety by advancing the quality of pathology and laboratory services through education, standard setting and ensuring laboratories meet or exceed regulatory requirements.
About ICON Central Laboratories
ICON Central Laboratories, a division of ICON plc, provides full service, global central laboratory services from core facilities in New York, Dublin, Singapore and India, as well as through quality affiliate laboratories in China and Japan. An extensive test menu of safety, esoteric and custom-developed assays, including global flow cytometry, is complemented by dedicated, sponsor-specific project teams and a single, comprehensive database for each study as well as a user-friendly, web-based, secure remote data access system. ICON Central Laboratories also offers a unique service to manage and compile laboratory data when a client’s study requires the use of local laboratories (iRIS).
For more information, visit
www.icolabs.com
.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
